Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Cutaneous Melanoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01894672
What this trial is testing

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Who this might be right for
Melanoma
Memorial Sloan Kettering Cancer Center 7
Testing effectiveness (Phase 2)Study completedNCT00289627
What this trial is testing

A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Who this might be right for
Melanoma
Bristol-Myers Squibb 155
Testing effectiveness (Phase 2)Study completedNCT00612664
What this trial is testing

Phase II, 2nd Line Melanoma - RAND Monotherapy

Who this might be right for
Melanoma
Bristol-Myers Squibb 158
Testing effectiveness (Phase 2)Active Not RecruitingNCT04417621
What this trial is testing

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals 134
Testing effectiveness (Phase 2)Study completedNCT03278665
What this trial is testing

4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy

Who this might be right for
Malignant Melanoma
4SC AG 40
Testing effectiveness (Phase 2)WithdrawnNCT00963664
What this trial is testing

Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma

Who this might be right for
MelanomaMalignant Melanoma
NeoPlas Innovation 250
Early research (Phase 1)Study completedNCT02138292
What this trial is testing

A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma

Who this might be right for
Melanoma
University of Texas Southwestern Medical Center 27
Early research (Phase 1)Study completedNCT02077114
What this trial is testing

Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma

Who this might be right for
Malignant Melanoma With Metastasis
Herlev Hospital 10
Not applicableStudy completedNCT00253708
What this trial is testing

Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer

Who this might be right for
Cancer
Beth Israel Deaconess Medical Center 39
Early research (Phase 1)Ended earlyNCT02628535
What this trial is testing

Safety Study of MGD009 in B7-H3-expressing Tumors

Who this might be right for
MesotheliomaBladder CancerMelanoma+10 more
MacroGenics 67
Early research (Phase 1)Ended earlyNCT03565406
What this trial is testing

A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Who this might be right for
Melanoma
NYU Langone Health 11
Testing effectiveness (Phase 2)Active Not RecruitingNCT03235245
What this trial is testing

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

Who this might be right for
Unresectable Stage III MelanomaStage IV Melanoma
European Organisation for Research and Treatment of Cancer - EORTC 271
Post-approval studies (Phase 4)Not Yet RecruitingNCT07459543
What this trial is testing

Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India

Who this might be right for
Unresectable MelanomaMetastatic Melanoma
Bristol-Myers Squibb 40
Testing effectiveness (Phase 2)Ended earlyNCT01754376
What this trial is testing

Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma

Who this might be right for
Melanoma
Massachusetts General Hospital 6
Testing effectiveness (Phase 2)Study completedNCT00591370
What this trial is testing

Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma

Who this might be right for
Melanoma
Memorial Sloan Kettering Cancer Center 51
Testing effectiveness (Phase 2)Ended earlyNCT01605162
What this trial is testing

Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

Who this might be right for
Wild Type BRAF Stage IV MelanomaUnresectable Stage III Melanoma
Eisai Inc. 8
Testing effectiveness (Phase 2)Ended earlyNCT02413827
What this trial is testing

Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma

Who this might be right for
Unresectable Stage III or Stage IV Melanoma
Celldex Therapeutics 9
Early research (Phase 1)WithdrawnNCT02915666
What this trial is testing

A Clinical Trial of Patients With Melanoma

Who this might be right for
Melanoma
University of Texas Southwestern Medical Center
Testing effectiveness (Phase 2)Looking for participantsNCT05136196
What this trial is testing

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Who this might be right for
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+22 more
National Cancer Institute (NCI)
Large-scale testing (Phase 3)Ended earlyNCT06587451
What this trial is testing

Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®

Who this might be right for
Melanoma
Sandoz 52
Next Page
150